|
MegaPro Biomedical completed capital increase and introduced new strategic partners
|
|
MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application
|
|
The company passed the approval of the Industrial Bureau of the Ministry of Economic Affairs for the second time as a new biotechnology drug company
|
|
MegaPro Biomedical Held a Pre-Emerging Stock Market Investors Briefing on Oct.14, 2021
|
|
MegaPro Biomedical MPB1523 Nano-MRI contrast agent makes a breakthrough and works with Stanford University in the CAR-T cell therapy experiment, which was published at the WMIC conference
|
|
MegaPro Medical’s new MRI contrast agent MPB-2043 has completed the first patient admission in Taiwan
|
|
MegaPro (6827)’s new drug MPB-2354 issues a press release on WMIS
|
|
MegaPro (6827) MPB-1734 completes the phase 1 of the last patient, press release
|
|
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
|
|
Expanding the application field again, MegaPro Biomedical IOP enters the field of cell therapy
|
